Wissenschaftliche Publikationen 2023 – 2018

Wissenschaftliche Publikationen sind in der Regel in Fachzeitschriften, Konferenzberichten oder Büchern zu finden und folgen einem strengen Peer-Review-Prozess, bei dem Experten*innen die Qualität und den wissenschaftlichen Wert der Arbeit bewerten, bevor sie veröffentlicht wird.

2024
  1. Zaccagnino A, Vynnytska-Myronovska B, Stöckle M, Junker, K (2024). Molecular and Functional Characterization of Reversible-Sunitinib-Tolerance State in Human Renal Cell Carcinoma. J Cell Mol Med. 28(9):e18329                                                                                                                                   
  2. Bastian L, Zeuschner P, Stöckle M, Junker K, Linxweiler J (2024). Tumor promoting effect of spheroids in an orthotopic prostate cancer mouse model. Sci Rep. 14(1):8835                    
  3. Flegar L, Huber J, Putz J, Thomas C, Apel H, Wullich B, Friedersdorff F, Fechner G, Ritter M, Kernig K, Weigand K, Heynemann H, Stöckle M, Zeuschner P; Working Group Kidney Transplantation of the German Association of Urology (2024). Multicenter evaluation of complex urinary diversion for renal transplantation: outcomes of complex surgical solutions. World J Urol. 2024 Apr 17;42(1):239                                                                                                                             
  4. Zeuschner P, Friedersdorff F, Siemer S, Stöckle M (2024). Robot-assisted kidney transplantation-what is new? Urologie.                                                                                                                           
  5. Zeuschner P, Mihm J, Sester U, Stöckle M, Friedersdorff F, Budde K, Yakac A, Thomas C, Huber J, Putz J, Flegar L (2024). Old for young kidney transplantation: a responsible option for our patients to reduce waiting time? World J Urol.                                                                                    
  6. Linxweiler J, Klümper N, Mink J, Eckstein M, Junker K (2024). Re: Assessment of PD-L1, TROP2, and NECTIN-4 Expression in Penile Squamous Cell Carcinoma. Eur Urol.                             
  7. Heinzelbecker J, Kaßmann K, Ernst S, Meyer-Mabileau P, Germanyuk A, Zangana M, Wagenpfeil G, Ohlmann CH, Cohausz M, Stöckle M, Lehmann J (2024). Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type. J Cancer Surviv.                                                                                                                                                     
  8. Schmidt J, Yakac A, Peters R, Friedersdorff F, Kernig K, Kienel A, Winterhagen FI, Köpp F, Foller S, DiQuilio F, Weigand K, Flegar L, Reimold P, Stöckle M, Putz J, Zeuschner P (2024). Radical Prostatectomy in Kidney Transplant Recipients-A Multicenter Experience. Eur Urol Open Sci.                                                                                                                                      
  9. Lohse S, Mink JN, Eckhart L, Hans MC, Jusufi L, Zwick A, Mohr T, Bley IA, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Lenhof HP, Naumann CM, Kalthoff H, Junker K (2024). The impact of the tumor microenvironment on the survival of penile cancer patients. Sci Rep. 2024 Sep 27;14(1):22050                                             
  10. Heinzelbecker J, Stöckle M (2024). Editorial Comment. J Urol. 211(3):434-435
  11. Diebolt CM, Schaudien D, Junker K, Krasteva-Christ G, Tschernig T, Englisch CN (2024). New Insights in the Renal Distribution Profile of TRPC3 - Of Mice and Men. Ann Anat. 252:152192   
  12. Eckstein M, Matek C, Wagner P, Erber R, Büttner-Herold M, Wild PJ, Taubert H, Wach S, Sikic D, Wullich B, Geppert CI, Compérat EM, Lopez-Beltran A, Montironi R, Cheng L, van der Kwast T, van Rhijn BWG, Amin MB, Netto GJ, Lehmann J, Stöckle M, Junker K, Hartmann A, Bertz S (2024). Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes. Eur Urol Oncol. 7(1):128-138                                                                                                                          
  13. Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators (Siemer S) (2024). Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 42(11):1222-1228
  14. Liedtke V, Stöckle M, Junker K, Roggenbuck D (2023). Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence? Autoimmunity Reviews. 23(3): 103511                                                                                                                                                                
  15. Belge G, Dumlupinar C, Nestler T, Klemke M, Törzsök P, Trenti E, Pichler R, Loidl W, Che Y, Hiester A, Matthies C, Pichler M, Paffenholz P, Kluth L, Wenzel M, Sommer J, Heinzelbecker J, Schriefer P, Winter A, Zengerling F, Kramer MW, Lengert M, Frey J, Heidenreich A, Wülfing C, Radtke A, Dieckmann KP (2024). Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study. Clin Cancer Res. 30(2):404-412                                                                                                                                                         
  16. Flegar L, Zeuschner P, Kernig K, Friedersdorff F, Putz J, Stöckle M, Giessing M, Apel H, Huber J (2024). Report on the 29th annual meeting of the kidney transplantation working group of the German Society of Urology in Marburg 2023. Urologie.                                                                            
  17. Cooke I, Abou Heidar N, Mahmood AW, Ahmad A, Jing Z, Stöckle M, Wagner AA, Roupret M, Kim E, Vasdev N, Balbay D, Rha KH, Aboumohamed A, Dasgupta P, Maatman TJ, Richstone L, Wiklund P, Gaboardi F, Li Q, Hussein AA, Guru K (2024). The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium. Urol Oncol. 42(4):117.e17-117.e25.              
  18. Pecoraro A, Basile G, Gallioli A, Territo A, Berquin C, Etcheverry B, Gaya JM, Vignolini G, Prudhomme T, Ortved M, Zeuschner P, Garcia-Baquero R, Rohrsted M, Stoeckle M, Doumerc N, Vigues F, Serni S, Campi R, Breda A (2024). Penetrance of Robot-assisted Kidney Transplantation in Surgical Practice at Referral European Transplant Centres: An Audit Within the ERUS-RAKT Working Group. European Association of Urology EAU Robotic Urology Section ERUS Robot-assisted Kidney Transplantation Working Group. Eur Urol Open Sci.                                                                                           
  19. Mekahli D, Müller RU, Marlais M, Wlodkowski T, Haeberle S, de Argumedo ML, Bergmann C, Breysem L, Fladrowski C, Henske EP, Janssens P, Jouret F, Kingswood JC, Lattouf JB, Lilien M, Maleux G, Rozenberg M, Siemer S, Devuyst O, Schaefer F, Kwiatkowski DJ, Rouvière O, Bissler J (2024). Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group. Nat Rev Nephrol.                                                          
  20. Pellegrino F, Martini A, Falagario UG, Rautiola J, Russo A, Mertens LS, Di Gianfrancesco L, Bravi CA, Vollemaere J, Abdeen M, Moschini M, Mendrek M, Kjøbli E, Buse S, Wijburg C, Touzani A, Ploussard G, Antonelli A, Schwenk L, Ebbing J, Vasdev N, Froelicher G, John H, Canda AE, Balbay MD, Stoll M, Edeling S, Berquin C, Van Praet C, Leyh-Bannurah SR, Siemer S, Stoeckle M, Mottrie A, D'Hondt F, Crestani A, Porreca A, Briganti A, Montorsi F, van der Poel H, Dacaestecker K, Gaston R, Hosseini A, Wiklund NP; Scientific Working Group of the Robotic Urology Section of the European Association of Urology (2024). How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group. BJU Int.                                       
  21. Uhlig A, Uhlig J, Leha A, Biggemann L, Bachanek S, Stöckle M, Reichert M, Lotz J, Zeuschner P, Maßmann A (2024). Radiomics and machine learning for renal tumor subtype assessment using multiphase computed tomography in a multicenter setting. Eur Radiol.              34(10):6254-6263                                                                                                                                                                                         
  22. Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M (2024). NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J Clin Oncol. 42(20):2446-2455                                                                                                               
  23. Dieckmann KP, Grobelny F, Soave A, Che Y, Nestler T, Matthies C, Heinzelbecker J, Winter A, Heidenreich A, Niemzok T, Dumlupinar C, Angerer M, Wülfing C, Paffenholz P, Belge G (2024). Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours. Eur Urol Focus                                                                                  
  24. Pellegrino F, Martini A, Falagario UG, Rautiola J, Russo A, Mertens LS, Di Gianfrancesco L, Bravi CA, Vollemaere J, Abdeen M, Moschini M, Mendrek M, Kjøbli E, Buse S, Wijburg C, Touzani A, Ploussard G, Antonelli A, Schwenk L, Ebbing J, Vasdev N, Froelicher G, John H, Canda AE, Balbay MD, Stoll M, Edeling S, Berquin C, Van Praet C, Leyh-Bannurah SR, Siemer S, Stoeckle M, Mottrie A, D'Hondt F, Crestani A, Porreca A, Briganti A, Montorsi F, van der Poel H, Dacaestecker K, Gaston R, Hosseini A, Wiklund NP; Scientific Working Group of the Robotic Urology Section of the European Association of Urology 2024). How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group. BJU Int. 133(6):673-677  
  25. Cano Garcia C, Hoeh B, Mandal S, Banek S, Klümper N, Schmucker P, Hahn O, Mattigk A, Ellinger J, Cox A, Becker P, Zeuschner P, Zengerling F, Erdmann K, Buerk BT, Kalogirou C, Flegar L (2024). First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany. Clin Genitourin Cancer. 22(4):102112                                                                                                                                                               
  26. Yu E, Ferrario C, Linch M, Stoeckle M, Laguerre B, Arranz S, Todenhöfer T, Fong P, Piulats J, Berry W,  Emmenegger U, Mourey L, Joshua A, Mar N, Appleman L, Conter H, Gravis G, Li X, Schloss C, Poehlein C, de Bono J (2024). Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D. Eur Urol Oncol                                                                                                                 
  27. Israel JS, Marcelin LM, Thomas C, Szczyrbová E, Fuessel S, Puhr M, Linxweiler J, Yalala S, Zwart WT, Baniahmad A, van Goubergen J, Itkonen HM, Sharp A, O'Neill E, Pretze M, Miederer M, Erb HHH (2024). Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium. J Exp Clin Cancer Res. 43(1):194
  28. Oing C, Rescigno P, Paffenholz P, Heinzelbecker J, Patrikidou A, Matulewicz RS, Huddart R (2024). Retroperitoneal Lymph Node Dissection in Patients with Stage II Seminomatous Germ Cell Tumour. Eur Urol Focus                                                                                                                                                 
  29. Englisch CN, Diebolt CM, Schaudien D, Klamminger GG, Kirstein E, Junker K, Wagner M, Tschernig T (2024). Proximal Tubular TRPC3 Immunostaining Is Reduced in Human Nephrocalcinosis. Lab Invest. 104(9):102109                                                                                                                                                     
  30. Bachanek S, Wuerzberg P, Biggemann L, Janssen TY, Nietert M, Lotz J, Zeuschner P, Maßmann A, Uhlig A, Uhlig J (2024). Renal tumor segmentation, visualization, and segmentation confidence using ensembles of neural networks in patients undergoing surgical resection. Eur Radiol. 
2023
  1. Mink JN, Khalmurzaev O, Pryalukhin A, Hölters S, Geppert C, Lohse S, Bende K, Lobo J, Henrique R, Loertzer H, Steffens J, Jerónimo C, Wunderlich H, Heinzelbecker J, Bohle R, Stöckle M, Matveev V, Hartmann A, Junker K (2023). Importance of HPV status and p16 for the prognosis of penile carcinoma. Aktuelle Urol. 54(4):274-284
  2. Mink JN, Khalmurzaev O, Pryalukhin A, Geppert CI, Lohse S, Bende K, Lobo J, Henrique R, Loertzer H, Steffens J, Jeronimo C, Wunderlich H, Heinzelbecker J, Bohle RM, Stöckle M, Matveev V, Hartmann A, Junker K (2023). Evaluation of Prognostic Parameters to Identify Aggressive Penile Carcinomas. Cancers. 15(19):4748
  3. Zaccagnino A, Vynnytska-Myronovska B, Stöckle M, Junker K (2023). An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. Int. J. Mol. Sci. 24(6):5648
  4. Zeuschner P, Böttcher C, Hager L, Linxweiler J, Stöckle M, Siemer S (2023). Last Resort from Nursing Shortage? Comparative Cost Analysis of Open vs. Robot-Assisted Partial Nephrectomies with a Focus on the Costs of Nursing Care. Cancers (Basel). 15(8):2291
  5. Heinzelbecker J, Spieler N, Kuehn M, Fischer C, Volkmer B, von Rundstedt F, Albers P, Becht E, Bannowsky A, Weber HM, Hofmann R, Müller M, Langbein S, Steiner G, Retz M, Kamradt J, Wagenpfeil G, Wellek S, Lehmann J, Stoeckle M (2023). Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial. Urol Oncol. 41(8):356.e19-356.e30
  6. Stöckle M (2023). Cystectomy versus trimodal therapy for bladder cancer. Urologie. 62(11):1215-1216
  7. Liedtke V, Rose L, Hiemann R, Nasser A, Rödiger S, Bonaventura A, Winkler L, Sowa M, Stöckle M, Schierack P, Junker K, Roggenbuck D (2023). Over-Expression of LEDGF/p75 in HEp-2 Cells Enhances Autoimmune IgG Response in Patients with Benign Prostatic Hyperplasia—A Novel Diagnostic Approach with Therapeutic Consequence? Int. J. Mol. Sci. 24(7):6166.
  8. Houenstein HA, Jing Z, Elsayed AS, Ramahi YO, Stöckle M, Wijburg C, Hosseini A, Wiklund P, Kim E, Kaouk J, Dasgupta P, Khan MS, Wagner AA, Syed JR, Peabody JO, Badani K, Richstone L, Mottrie A, Maatman TJ, Balbay D, Redorta JP, Rha KH, Gaboardi F, Rouprêt M, Aboumohamed A, Hussein AA, Guru KA (2023). Analysis of Complications After Robot-Assisted Radical Cystectomy Between 2002-2021. Urology. 171:133-139
  9. Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B, Arranz JA, Oudard S, Massard C, Heinzelbecker J, Nordquist LT, Carles J, Kolinsky MP, Augustin M, Gurney H, Tafreshi A, Li XT, Qiu P, Poehlein CH, Schloss C, de Bono JS (2023). Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. Eur Urol. 83(1):15-26
  10. Rosar F, Burgard C, Linxweiler J, Wagner M, Ezziddin S (2023). Histologically Confirmed Testicular Metastasis Revealed by [89Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging. Diagnostics (Basel). 13(7):1352
  11. Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, Briganti A, Burger M, Choudhury A, Colecchia M, De Santis M, Fanti S, Fonteyne V, Gallucci M, Rivas JG, Huddart R, Junker K, Kroeze S, Loriot Y, Merseburger A, Montironi R, Necchi A, Oing C, Oldenburg J, Ost P, Pinkawa M, Ribal MJ, Rouprêt M, Thoeny H, Zilli T, Hoskin P (2023). Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 84(4):381-389.
  12. Martini A, Falagario UG, Russo A, Mertens LS, Di Gianfrancesco L, Bravi CA, Vollemaere J, Abdeen M, Mendrek M, Kjøbli E, Buse S, Wijburg C, Touzani A, Ploussard G, Antonelli A, Schwenk L, Ebbing J, Vasdev N, Froelicher G, John H, Canda AE, Balbay MD, Stoll M, Edeling S, Witt JH, Leyh-Bannurah SR, Siemer S, Stoeckle M, Mottrie A, D'Hondt F, Crestani A, Porreca A, van der Poel H, Decaestecker K, Gaston R, Peter Wiklund N, Hosseini A; Scientific Working Group of the Robotic Urology Section of the European Association of Urology (2023). Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males. Eur Urol.
  13. Burgard C, Rosar F, Marlowe RJ, Bartholomä M, Dewes S, Schaefer-Schuler A, Linxweiler J, Khreish F, Ezziddin S (2023). Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations. Cancers (Basel). 15(9):2592
  14. Gloger S, Wagner C, Leyh-Bannurah SR, Siemer S, Arndt M, Stolzenburg JU, Franz T, Ubrig B (2023). High BMI and Surgical Time Are Significant Predictors of Lymphocele after Robot-Assisted Radical Prostatectomy. Cancers (Basel). 15(9):2611
  15. Mikuteit M, Zschäbitz S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos F, Walter B, Otto W, Burger M, Erlmeier M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S; German Network Of Kidney Cancer (2023). Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma. Urol Int. 107(7):713-722
  16. Majewski M, Paffenholz P, Ruf C, Che Y, Seidel C, Heinzelbecker J, Schmelz HU, Matthies C, Albers P, Bokemeyer C, Heidenreich A, Pichler M, Nestler T; GTCSG (German Testicular Cancer Study Group) (2023). Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment. Cancer Med. 12(16):16829-16836
  17. Flockerzi FA, Hohneck J, Saar M, Bohle RM, Stahl PR (2023). SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis. Diagnostics (Basel). 13(13):2211.
  18. Eckstein M, Matek C, Wagner P, Erber R, Büttner-Herold M, Wild PJ, Taubert H, Wach S, Sikic D, Wullich B, Geppert CI, Compérat EM, Lopez-Beltran A, Montironi R, Cheng L, van der Kwast T, van Rhijn BWG, Amin MB, Netto GJ, Lehmann J, Stöckle M, Junker K, Hartmann A, Bertz S (2023). Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes. Eur Urol Oncol.
  19. Majewski M, Paffenholz P, Ruf C, Che Y, Seidel C, Heinzelbecker J, Schmelz HU, Matthies C, Albers P, Bokemeyer C, Heidenreich A, Pichler M, Nestler T; GTCSG (German Testicular Cancer Study Group) (2023). Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment. Cancer Med. 12(16):16829-16836
  20. Hoeh B, Garcia CC, Banek S, Klümper N, Cox A, Ellinger J, Schmucker P, Hahn O, Mattigk A, Zengerling F, Becker P, Erdmann K, Buerk BT, Flegar L, Huber J, Kalogirou C, Zeuschner P (2023). Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions. Clin Transl Immunology.
  21. Diebolt CM, Schaudien D, Junker K, Krasteva-Christ G, Tschernig T, Englisch CN (2023). New Insights in the Renal Distribution Profile of TRPC3 - Of Mice and Men. Ann Anat. doi: 10.1016/j.aanat.2023.152192
  22. Belge G, Dumlupinar C, Nestler T, Klemke M, Törzsök P, Trenti E, Pichler R, Loidl W, Che Y, Hiester A, Matthies C, Pichler M, Paffenholz P, Kluth L, Wenzel M, Sommer J, Heinzelbecker J, Schriefer P, Winter A, Zengerling F, Kramer MW, Lengert M, Frey J, Heidenreich A, Wülfing C, Radtke A, Dieckmann KP (2023). Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study.Clin Cancer Res.. doi: 10.1158/1078-0432.

 

 

 

 

2022
  1. Nini A, Boschheidgen M, Hiester A, Winter C, Antoch G, Schimmöller L, Albers P (2022). Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND).World J Urol.    40(2):349-354    
  2. Al-Kailani Z, Linxweiler J, Siemer S, Stöckle M, Saar M (2022). Deferred prostatectomy after active surveillance-results from a single center. Urologie. 61:753-758
  3. Heinzelbecker J, Schmidt S, Lackner J, Busch J, Bokemeyer C, Classen J, Dieing A, Hakenberg O, Krege S, Papachristofilou A, Pfister D, Ruf C, Schmelz H, Schmidberger H, Souchon R, Winter C, Zengerling F, Kliesch S, Albers P, Oing C (2022). Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol. 40(12):2829-2841
  4. Junker K (2022). Liquid biopsy to indvidualise therapy in advanced bladder cancer. Aktuelle Urol. 53(2):183-187
  5. Linxweiler J, Hajili T, Zeuschner P, Menger MD, Stöckle M, Junker K*, Saar M* (2022). Primary Tumor Resection Decelerates Disease Progression in an Orthotopic Mouse Model of Metastatic Prostate Cancer. Cancers (Basel); 14(3):737
  6. Zeuschner P, Becker P, Heinzelbecker J, Linxweiler J, Siemer S, Stöckle M, Saar M (2022). Robot-assisted surgery as an elective-fascinating lesson(s)? Urologe A. 61:400-406
  7. Linxweiler J, Hajili T, Saar M, Maßmann C, Junker K, Stöckle M (2022). Influence of local treatment on the biology of advanced prostate cancer: Treatment of the primary tumor may delay hormone resistance of metastases. Urologe A. 61(5):518-525
  8. Junker K, Hallscheidt P, Wunderlich H, Hartmann A (2022). Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations. World J Urol. 40(10):2373-2379
  9. Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Junker K, Zillmann R, Rüssel C, Hellmis E, Suttmann H, Janssen M, Marin J, Hübner A, Mathers M, Gleißner J, Scheffler M, Feyerabend S, Telle J, Klier J, Stöckle M (2022). LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis. 25(4):778-784
  10. Zeuschner P, Junker K (2022). Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma. Eur Urol Focus. 8(4):907-909
  11. Stöckle M (2022). Re: Tranexamic Acid in Patients Undergoing Noncardiac Surgery. Eur Urol. 82(6):657-658
  12. Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A (2022). Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. Eur Urol Oncol. 5(3):285-295
  13. Hentrich MU, Bower M, Daugaard G, Dieing A, Bickel M, Berretta M, Lesmeister F, Jurinovic V, Stoehr A, Heinzelbecker J, Krznaric I, Dieckmann KP, Necchi A, Maroto Rey P, Rockstroh JK, Brito M, Pfister D, Hoffmann C (2022). Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. Cancer; 128(2):260-268
  14. Burdett S, Fisher DJ, Vale CL, Bono AV, Clarke NW, Cognetti F, Collette L, Cote RJ, Goebell PJ, Groshen S, Lehmann J, Parmar MKB, Rolevich AI, Sonntag RW, Sternberg CN, Stockle M, Studer UE, Torti FM, Zhegalik AG, Tierney JF; Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group (2022). Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol. 81(1):50-61
  15. Gopalakrishnan D, Elsayed AS, Hussein AA, Jing Z, Li Q, Wagner AA, Aboumohamed A, Roupret M, Balbay D, Wijburg C, Stockle M, Dasgupta P, Khan MS, Wiklund P, Hosseini A, Peabody J, Shigemura K, Trump D, Guru KA, Chatta G (2022). Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium. Int J Urol. 29(3):197-205
  16. Erlmeier F, Bruecher B, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Mondorf Y, Ivanyi P, Mikuteit M, Steffens S; German Network Of Kidney Cancer (2022). cMET - a prognostic marker in papillary renal cell carcinoma? Hum Pathol. 121:1-10
  17. Hoeh B, Schmucker P, Klümper N, Hahn O, Zeuschner P, Banek S, Karakiewicz PI, Ellinger J, Heinzelbecker J, Hölzel M, Strauß A, Zengerling F, Mattigk A, Kalogirou C (2022). Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Urol Int.
  18. Busch J, Schmidt S, Albers P, Heinzelbecker J, Kliesch S, Lackner J, Pfister D, Ruf C, Winter C, Zengerling F, Beyersdorff D (2022). Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review. World J Urol. 40(12):2843-2852
  19. Mikuteit M, Zschäbitz S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Steffens S, Erlmeier F (2022). The prognostic impact of Claudin 6 in papillary renal cell carcinoma. Pathol Res Pract. 231:153802
  20. Pfister D, Oechsle K, Schmidt S, Busch J, Bokemeyer C, Heidenreich A, Heinzelbecker J, Ruf C, Winter C, Zengerling F, Kliesch S, Albers P, Oing C (2022). First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group. World J Urol. 40(12):2853-2861
  21. Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S (2022). 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging; 49(3):1075-1085
  22. Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M (2022). C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. Eur J Cancer. 30;167:13-22.
  23. Dieckmann KP, Pokrivcak T, Geczi L, Niehaus D, Dralle-Filiz I, Matthies C, Dienes T, Zschäbitz S, Paffenholz P, Gschliesser T, Pichler R, Mego M, Bader P, Zengerling F, Heinzelbecker J, Krausewitz P, Krege S, Aurilio G, Aksoy C, Hentrich M, Seidel C, Törzsök P, Nestler T, Majewski M, Hiester A, Buchler T, Vallet S, Studentova H, Schönburg S, Niedersüß-Beke D, Ring J, Trenti E, Heidenreich A, Wülfing C, Isbarn H, Pichlmeier U, Pichler M (2022). Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Ther Adv Med Oncol. 14:1-13
  24. Gloger S, Ubrig B, Boy A, Leyh-Bannurah SR, Siemer S, Arndt M, Stolzenburg JU, Franz T, Oelke M, Witt JH (2022). Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomised Multicentre Trial ProLy. J Urol. 208:333-340
  25. Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA, Bartholomä M, Khreish F, Ezziddin S (2022). Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. Cancers (Basel). 14(7):1696
  26. Winter C, Zengerling F, Busch J, Heinzelbecker J, Pfister D, Ruf C, Lackner J, Albers P, Kliesch S, Schmidt S, Bokemeyer C (2022). How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence. World J Urol. 40(12):2863-2878
  27. Mondorf Y, Mikuteit M, Ivanyi P, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief CG, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Steffens S, Erlmeier F (2022). The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. Urol Int. 106:1168-1176
  28. Elsayed AS, Iqbal U, Jing Z, Houenstein HA, Wijburg C, Wiklund P, Kim E, Stöckle M, Kelly J, Dasgupta P, Wagner AA, Kaouk J, Badani KK, Redorta JP, Mottrie A, Peabody JO, Rouprêt M, Balbay D, Richstone L, Rha KH, Aboumohamed A, Li Q, Hussein AA, Guru KA (2022). Relapses Rates and Patterns for Pathological T0 After Robot-Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. Urology. 166:177-181
  29. Zschäbitz S, Erlmeier F, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Mondorf Y, Hartmann A, Ivanyi P, Steffens S (2022). Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort. J Cancer. 13(6):1706-1712
  30. Vitale G, Caraglia M, Jung V, Kamradt J, Gentilini D, Di Martino MT, Dicitore A, Abate M, Tagliaferri P, Itro A, Ferro M, Balsamo R, De Sio M, Facchini G, Persani L, Schmitt K, Saar M, Stöckle M, Unteregger G, Zappavigna S (2022). Molecular Characterization of Cancer Associated Fibroblasts in Prostate Cancer. Cancers; 14(12):2943
  31. Diekstra MHM, Swen JJ, van der Zanden LFM, Vermeulen SH, Boven E, Mathijssen RHJ, Fukunaga K, Mushiroda T, Hongo F, Oosterwijk E, Cambon-Thomsen A, Castellano D, Fritsch A, Donas JG, Rodriguez-Antona C, Ruijtenbeek R, Radu MT, Eisen T, Junker K, Roessler M, Jaehde U, Miki T, Böhringer S, Kubo M, Kiemeney LALM, Guchelaar HJ (2022). Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers. 14(12):2838
  32. Zengerling F, Beyersdorff D, Busch J, Heinzelbecker J, Pfister D, Ruf C, Winter C, Albers P, Kliesch S, Schmidt S (2022). Prognostic factors in patients with clinical stage I nonseminoma-beyond lymphovascular invasion: a systematic review. World J Urol. 40(12):2879-2887
  33. Ruf CG, Schmidt S, Kliesch S, Oing C, Pfister D, Busch J, Heinzelbecker J, Winter C, Zengerling F, Albers P, Oechsle K, Krege S, Lackner J, Dieckmann KP (2022). Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review. World J Urol. 40(12):2889-2900
  34. Zschäbitz S, Mikuteit M, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S (2022). Expression of nectin-4 in papillary renal cell carcinoma. Discov Oncol. 22;13(1):90
  35. Borkowetz A, Linxweiler J, Fussek S, Wullich B, Saar M; German Prostate Cancer Consortium (DPKK) (2022). The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey. Urol Int. 106:1126-1135
  36. Harke NN, Kuczyk MA, Huusmann S, Schiefelbein F, Schneller A, Schoen G, Wiesinger C, Pfuner J, Ubrig B, Gloger S, Osmonov D, Eraky A, Witt JH, Liakos N, Wagner C, Hadaschik BA, Radtke JP, Al Nader M, Imkamp F, Siemer S, Stöckle M, Zeuschner P (2022). Impact of Surgical Experience Before Robot-assisted Partial Nephrectomy on Surgical Outcomes: A Multicenter Analysis of 2500 Patients. Eur Urol Open Sci. 46:45-52.
2021

Veröffentlichungen in nationalen und internationalen Wissenschaftszeitschriften 2021

  1. Zeuschner P, Meyer I, Siemer S, Stoeckle M., Wagenpfeil G, Wagenpfeil S, Saar M, Janssen M. (2021) Three different learning curves have an independent impact on perioperative outcomes after robotic partial nephrectomy – a comparative analysis. Ann Surg Oncol. 28(2):1254-1261
  2. Zeuschner P, Greguletz L, Meyer I, Linxweiler J, Janssen M, Wagenpfeil G, Wagenpfeil S, Siemer S, Stöckle M, Saar M (2021). Open versus robot-assisted partial nephrectomy: a longitudinal comparison of 880 patients over 10 years. Int J Med Robot. 17(1):1-8
  3. Abdeen M, Janssen M, Al-Kailani Z, Saar M, Siemer S, Stöckle M, Aßmann G, Linxweiler J (2021). When a urological emergency indicates an internal medical crisis: Priapism as the first clinical manifestation of leukemia. Urologe A. 60(1):67-70
  4. Niklas C, Saar M, Nini A, Linxweiler J, Siemer S, Junker K, Stoeckle M (2021). Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance? World J Urol. 39(9):3231-3237
  5. Linxweiler J, Sprenk J, Cascetta K, Pryalukhin A, Hölters S, Zeuschner P, Nini A, Al-Kailani Z, Ezziddin S, Bohle RM, Fries P, Ohlmann CH, Heinzelbecker J, Siemer S, Stöckle M, Junker K*, Saar M* (2021). Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management. J Urol. 206(1):88-96
  6. Ayoubian H, Heinzelmann J, Hölters S, Khalmurzaev O, Pryalukhin A, Loertzer P, Heinzelbecker J, Lohse S, Geppert C, Loertzer H, Wunderlich H, Bohle RM, Stöckle M, Matveev VB, Hartmann A, Junker K (2021). miRNA Expression Characterizes Histological Subtypes and Metastasis in Penile Squamous Cell Carcinoma. Cancers. 13(6):1480
  7. Zeuschner P, Linxweiler J, Mohr R, van Heemskerk S, Wagenpfeil G, Wagenpfeil S, Ohlmann C, Siemer S, Stöckle M, Saar M (2021). Robot-assisted versus open radical cystectomy: A cohort study on perioperative outcomes accounting for stage selection bias and surgical experience. Int J Med Robot. 17(4):e2258
  8. Zeuschner P, Vollmer SG, Linxweiler J, Wagenpfeil G, Wagenpfeil S, Saar M, Siemer S, Stöckle M, Heinzelbecker J (2021). Robot-assisted versus open radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: A retrospective cohort study across ten years. Surg Oncol.
  9. Ohlmann CH, Saar M, Pierchalla LC, Zangana M, Bonaventura A, Stöckle M, Siemer S, Heinzelbecker J (2021). Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours. Sci Rep. 11(1):10700
  10. Zeuschner P, Hölters S, Stöckle M., Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm M-O, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Staehler M, Junker K (2021). Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers. 13(11): 2594.
  11. Zeuschner P, Siemer S (2021). Robot-assisted surgery for renal cell carcinoma - today a standard? Aktuelle Urol. 52(5):464-473
  12. Zeuschner P, Zaccagnino A, Junker K (2021). Biomarkers for renal cell tumours. Aktuelle Urol. 52(5):452-463
  13. Heinzelbecker J, Ruf C (2021). non-metastasised clincial stage I testicular germ cell tumours: Patient information, suitability and limitations of surveillance. Urologe A. 60(7):854-861
  14. Zeuschner P, Stöckle M, Peters R, Miller K, Liefeldt L, Halleck F, Budde K, Hennig L, Friedersdorff F (2021). Does the Side Matter? A Retrospective Cohort Study Comparing Left and Right Pure Laparoscopic Donor Nephrectomies. Urol Int. 105(11-12):1076-1084
  15. Linxweiler J, Kolbinger A, Himbert D, Zeuschner P, Saar M, Stöckle M, Junker K (2021). Organ-Specific Uptake of Extracellular Vesicles Secreted by Urological Cancer Cells. Cancers.13(19):4937
  16. Nini A, Muttin F, Cianflone F, Carenzi C, Lucianó R, Catena M, Larcher A, Salvioni M, Cazzaniga W, Pederzoli F, Matloob R, Colombo R, Paganelli M, Salonia A, Briganti A, Doglioni C, Zangrillo A, De Cobelli F, Rigatti P, Freschi M, Cornero G, Nicoletti R, Aldrighetti L, Montorsi F, Capitanio U, Bertini R (2021). Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. Minerva Urol Nefrol. 73(6):746-753
  17. Prudhomme T, Beauval JB, Lesourd M, Roumiguié M, Decaestecker K, Vignolini G, Campi R, Serni S, Territo A, Gausa L, Tugcu V, Sahin S, Alcaraz A, Musquera M, Stockle M, Janssen M, Fornara P, Mohammed N, Del Bello A, Kamar N, Sallusto F, Breda A, Doumerc N (2021). Robotic-assisted kidney transplantation in obese recipients compared to non-obese recipients: the European experience. World J Urol. 39(4):1287-1298
  18. Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M (2021). Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World J Urol. 39(1):65-72
  19. Musquera M, Peri L, Ajami T, Breda A, Campi R, Tugcu V, Decaestecker K, Stockle M, Fornara P, Doumerc N, Vigues F, Barod R, Desender L, Territo A, Serni S, GrazianoVignolini, Sahin S, Zeuschner P, Banga N, Alcaraz A (2021). Robotic Assisted Kidney Transplantation: Update from the ERUS series. BJU Int. 127(2):222-228
  20. Erlmeier F, Steffens S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Ivanyi P; (German Network Of Kidney Cancer) (2021). Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Clin Genitourin Cancer. 19(1):53-59
  21. Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M (2021). Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). J Cancer Res Clin Oncol. 147(1):235-242
  22. Staehler M, Stöckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Brüning F, Goebell PJ, Augustin M, Roos F, Benz-Rüd I, Marschner N, Grünwald V (2021). Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Int J Cancer. 148(7):1685-1694
  23. Bernhard MC, Zwick A, Mohr T, Gasparoni G, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Naumann CM, Kalthoff H, Junker K, Smola S, Lohse S (2021). The HPV and p63 status in penile cancer are linked with the infiltration and therapeutic availability of neutrophils. Mol Cancer Ther. 20(2):423-437
  24. Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021). Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urol Int. 105(3-4):169-180
  25. Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021). Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. Urol Int. 105(3-4):181-191
  26. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C (2021). The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World J Urol. 39(9):3407-3414
  27. Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F (2021). Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics. 11(9):4050-4060
  28. Casper M, Linxweiler M, Linxweiler J, Zimmermann R, Glanemann M, Lammert F, Weber SN (2021). SEC62 and SEC63 Expression in Hepatocellular Carcinoma and Tumor-Surrounding Liver Tissue. Visc Med. 37(2):110-115.
  29. Erdbrügger U, Blijdorp CJ, Bijnsdorp IV, Borràs FE, Burger D, Bussolati B, Byrd JB, Clayton A, Dear JW, Falcón-Pérez JM, Grange C, Hill AF, Holthöfer H, Hoorn EJ, Jenster G, Jimenez CR, Junker K, Klein J, Knepper MA, Koritzinsky EH, Luther JM, Lenassi M, Leivo J, Mertens I, Musante L, Oeyen E, Puhka M, van Royen ME, Sánchez C, Soekmadji C, Thongboonkerd V, van Steijn V, Verhaegh G, Webber JP, Witwer K, Yuen PST, Zheng L, Llorente A, Martens-Uzunova ES (2021). Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. J Extracell Vesicles. 10(7):e12093
  30. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators (Stoeckle M, Ohlmann C) (2021).  Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22(7):931-945
  31. Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S (2021). Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 48(1):103-112
  32. Rosar F, Krause J, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Ezziddin S, Khreish F (2021). Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceutics. 13(5):722
  33. Iqbal U, Elsayed AS, Jing Z, Stoeckle M, Wijburg C, Wiklund P, Hosseini A, Dasgupta P, Khan MS, Hemal A, Kim EH, Wagner AA, Gaboardi F, Rha KH, Maatman T, Balbay D, Li Q, Hussein A, Guru KA Dr (2021). Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Endourol. 35(10):1541-1547
  34. Rosar F, Kochems N, Bartholomä M, Maus S, Stemler T, Linxweiler J, Khreish F, Ezziddin S (2021). Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers (Basel). 13(12):3095
  35. Nelskamp A, Schnurr B, Germanyuk A, Sterz J, Lorenz J, Sader R, Rüsseler M, Seifert LB (2021). Comparison of 'Mental training' and physical practice in the mediation of a structured facial examination: a quasi randomized, blinded and controlled study. BMC Med Educ. 23;21(1):178
  36. Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmitz W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A (2021). MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 12(1):5066
  37. Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S (2021). Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. Biomolecules. 11(8):1099    4,879/0,232
  38. Khreish F, Ribbat K, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Schreckenberger M, Ezziddin S, Rosar F (2021). Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT. Cancers (Basel). 13(16):4134
  39. Schulz GB, Stief CG, Saar M, Vögeli TA, Todenhöfer T, Knüchel R, Gaisa NT (2021). Molecular diagnostics of bladder cancer-practical ramifications. Urologe A. 60(10):1349-1358
  40. Bley IA, Zwick A, Hans MC, Thieser K, Wagner V, Ludwig N, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Naumann CM, Kalthoff H, Junker K, Smola S, Lohse S (2021). IDKK1 inhibits canonical Wnt signaling in human papillomavirus-positive penile cancer cells. Transl Oncol. 15(1):101267
  41. Kornienko K, Siegel F, Borkowetz A, Hoffmann MA, Drerup M, Lieb V, Bruendl J, Höfner T, Cash H, von Hardenberg J, Westhoff N; GESRU Academics Prostate Cancer Group (2021). Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study. Prostate Cancer Prostatic Dis.
  42. Klümper N*, Schmucker P*, Hahn O, Höh B, Mattigk A, Banek S, Ellinger J, Heinzelbecker J, Sikic D, Eckstein M, Strauß A, Zengerling F, Hölzel M, Zeuschner P, Kalogirou C (2021). C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma. Clin Transl Immunology.10(12):e1358
2020

Veröffentlichungen in nationalen und internationalen Wissenschaftszeitschriften 2020

  1. Himbert D, Zeuschner P, Ayoubian H, Heinzelmann J, Stöckle M, Junker K (2020).  Characterization of CD147, CA9, and CD70 as tumor-specific markers on extracellular vesicles in clear cell renal cell carcinoma. Diagnostics 10(12): 1034
  2. Stöckle M(2020). Neoadjuvant chemohormonal therapy prior to prostatectomy in high-risk prostate cancer-is biochemical recurrence an adequate surrogate marker for clinical benefit? Urologe A
  3. Zeuschner P, Linxweiler J, Junker K (2020). Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn. 20(2): 151-167
  4. Zeuschner P, Saar M, Janssen M (2020). ASO Author Reflection: Learning Curves in Robotic Partial Nephrectomy-Not Only the Surgeon Counts. Ann Surg Oncol
  5. Zeuschner P, Sester U, Stöckle M, Saar M, Zompolas I, El-Bandar N, Liefeldt L, Budde K, Öllinger R, Ritschl P, Schlomm T, Mihm J, Friedersdorff F (2020). Should We Perform Old-for-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay. J Clin Med. 9(6)
  6. Linxweiler J, Hajili T, Körbel C, Berchem C, Zeuschner P, Müller A, Stöckle M, Menger M,  Junker K*, Saar M* (2020). Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep
  7. Zeuschner P, Siemer S, Stöckle M, Saar M. (2020) Die ersten 50 roboter-assistierten Donornephrektomien. Urologe A
  8. Saar M, Linxweiler J, Borkowetz A, Fussek S, Urbanova K, Bellut L, Kristiansen G, Wullich B; German Prostate Cancer Consortium (DPKK) (2020). Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey. Urol Int.
  9. Ernst S, Heinzelmann J, Bohle RM, Weber G, Stöckle M, Junker K*, Heinzelbecker J* (2020). The metastatic potential of seminomatous germ cell tumours is associated with a specific microRNA pattern. Andrology
  10. Junker K, Eckstein M, Fiorentino M, Montironi R (2020). PD1/PD-L1 axis in uro-oncology. Curr Drug Targets.
  11. Zeuschner P, Hennig L, Peters R, Saar M, Linxweiler J, Siemer S, Magheli A, Kramer J, Liefeldt L, Budde K, Schlomm T, Stöckle M, Friedersdorff F (2020). Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases. J Clin Med. 26;9(6)
  12. Zeuschner P, Siemer S (2020). New aspects in the treatment of localized renal cell carcinoma. Urologe A.
  13. Linxweiler J, Junker K (2020). Extracellular vesicles in urological malignancies: an update. Nat Rev Urol.
  14. Zeuschner P, Siemer S, Stöckle M (2020). Robot-assisted kidney transplantation. Urologe A
  15. Kriegsmann M, Casadonte R, Maurer N, Stoehr C, Erlmeier F, Moch H, Junker K, Zgorzelski C, Weichert W, Schwamborn K, Deininger SO, Gaida M, Mechtersheimer G, Stenzinger A, Schirmacher P, Hartmann A, Kriegsmann J, Kriegsmann K (2020). Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. J Cancer
  16. Hiester A, Nini A, Arsov C, Buddensieck C, Albers P (2020). Robotic-Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. J Urol.
  17. Montorsi F, Bandini M, Briganti A, Dasgupta P, Gallina A, Gallucci M, Gill IS, Guru KA, Hemal A, Menon M, Moschini M, Murphy DG, Parekh DJ, Patel HD, Patel HRH, Stöckle M, Tewari AK, Wijburg CJ, Wiklund P, Wilson TG, Mottrie A; EAU Robotic Urology Section Scientific Working Group (2020). Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. Eur Urol.
  18. Massmann A, Fries P, Shayesteh-Kheslat R, Buecker A, Stöckle M, Niklas C (2020). Life-threatening arterioureteral fistula treatment by endovascular complete anatomic iliac artery bifurcation reconstruction.  J Vasc Surg Cases Innov Tech. 6(2):199-204
  19. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A (2020). Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol.               
  20. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A (2020). Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. Eur Urol.
  21. Hoffmann M.J., Taubert H., Junker K. (2020) Molekulare Grundlagen der Karzinogenese und molekularbiologische Untersuchungsmethoden. In: Rübben H., Hakenberg O., Grimm MO., Burger M. (eds) Uroonkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg
  22. Fornara P, Stöckle M (2020). Kidney transplantation and organ donation. Urologe A. 59(1):2
  23. Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C, Ezziddin S (2020). New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 47(3):687-694
  24. Outeiro-Pinho G, Barros-Silva D, Aznar E, Sousa AI, Vieira-Coimbra M, Oliveira J, Gonçalves CS, Costa BM, Junker K, Henrique R, Jerónimo C (2020). MicroRNA-30a-5p me: A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma in Tissue and Urine Samples. J Exp Clin Cancer Res. 39(1):98.
  25. Rosar F, Ribbat K, Ries M, Linxweiler J, Bartholomä M, Maus S, Schreckenberger M, Ezziddin S, Khreish F (2020). Neuron-specific Enolase Has Potential Value as a Biomarker for [ 18 F]FDG/[ 68 Ga]Ga-PSMA-11 PET Mismatch Findings in Advanced mCRPC Patients. EJNMMI Res.10(1):52
  26. Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, Saar M, Bartholomä M, Ezziddin S (2020). Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177 Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging
  27. Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann KP, Brito M, Ruf C, Oing C, Bokemeyer C. (2020). Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). Eur J Cancer. 132:127-135
  28. Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, Peabody JO, Wijburg CJ, Wagner A, Canda AE, Khan MS, Scherr D, Schanne F, Maatman TJ, Kim E, Mottrie A, Aboumohamed A, Gaboardi F, Pini G, Kaouk J, Yuh B, Rha KH, Hemal A, Palou Redorta J, Badani K, Saar M, Stockle M, Richstone L, Roupret M, Balbay D, Dasgupta P, Menon M, Guru KA (2020). A Comparative Propensity-Score Matched Analysis of Perioperative Outcomes of Intracorporeal versus Extracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. BJU Int.
  29. Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M (2020). Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World J Urol.
  30. Aldhaam NA, Elsayed AS, Jing Z, Richstone L, Wagner AA, Rha KH, Yuh B, Palou J, Khan MS, Menon M, Roupret M, Balbay D, Hosseini A, Wiklund P, Gaboardi F, Maatman TJ, Mottrie A, Wijburg C, Stöckle M, Hemal A, Kim E, Kaouk J, Hussein AA, Guru KA (2020). Neoadjuvant Chemotherapy Is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Utilization from the IRCC. J Urol. 203(1):57-61
  31. Pein U, Girndt M, Markau S, Fritz A, Breda A, Stöckle M, Mohammed N, Kawan F, Schumann A, Fornara P, Weigand K (2019). Minimally invasive robotic versus conventional open living donor kidney transplantation. World J Urol
  32. Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholomä M, Ezziddin S (2019). 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging.
2019

Veröffentlichungen in nationalen und internationalen Wissenschaftszeitschriften 2019

  1. Hajili T, Ohlmann CH, Linxweiler J, Niklas C, Janssen M, Siemer S, Stoeckle M, Saar M. (2019). Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up. BJU Int. 123:58–6
  2. Zeuschner P, Ueberdiek S, Pryalukhin A, Veith C, Saar M, Smola S, Bohle RM, Junker K, Stöckle M, Heinzelbecker J (2019). Human Papillomavirus-Associated Invasive Condylomas in a Man with Immunosuppressive Comorbidities.  Urol Int. 102(2):238-24
  3. Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Füssel S, Novotny V, Toma M, Gajda M, Lehmann J, Wunderlich H, Grimm MO, Stöckle M, Junker K (2019). A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. J Cancer Res Clin Oncol. 145(4):811-82
  4. Linxweiler J, Hammer M, Muhs S, Kohn M, Pryalukhin A, Veith C, Bohle RM, Stöckle M, Junker K, Saar M (2019). Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer. J Cancer Res Clin Oncol. 145(3), 551-55
  5. Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M (2019). Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol. 75(4):604-61
  6. Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A (2019). High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Hum Pathol. 83:212-22
  7. Grimm J*, Zeuschner P*, Janssen M, Wagenpfeil S, Hartmann A, Stöhr C, Keck B, Kahlmeyer A, Stöckle M, Junker K (2019). Metastatic risk stratification of clear cell renal cell carcinoma patients based on genomic aberrations. Genes Chrom Cancer 58(9):612-61
  8. Hölters S*, Khalmurzaev O*, Pryalukhin A*, Loertzer P, Janssen M, Heinzelbecker J,  Ueberdiek S, Pfuhl T, Smola S, Agaimy A, Geppert C, Loertzer H, Krah X,  Wunderlich H, Wagenpfeil S, Bohle R, Stöckle M, Matveev V, Hartmann*, A, Junker K* (2019). Challenging the prognostic impact of the new WHO and TNM classifications with special emphasis on HPV status in penile carcinoma. Virchows Archiv    475(2):211-22
  9. Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G (2019). Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 37(16):1412-142
  10. Stöckle M (2019). Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. Eur Uro
  11. Junker K, Zeuschner P (2019). Personalisierte Medizin bei Nierenzelltumoren. Aktuelle Urol. 50(5):513-52
  12. Heinzelmann J, Arndt M, Pleyers R, Fehlmann T, Hoelters S, Zeuschner P, Vogt A, Pryalukhin A, Schaeffeler E, Bohle RM, Gajda M, Janssen M, Stoeckle M, Junker K (2019). 4-miRNA Score Predicts the Individual Metastatic Risk of Renal Cell Carcinoma Patients. Ann Surg Oncol.  26(11): 3765-377
  13. Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, Osei J, Kaouk J, Redorta JP, Menon M, Peabody J, Dasgupta P, Khan MS, Mottrie A, Stöckle M, Hemal A, Richstone L, Hosseini A, Wiklund P, Schanne F, Kim E, Rha KH, Guru KA (2019). Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol. 202(5):927-93
  14. Rieken M, Herrmann TRW, Füllhase C (2019). Surgical treatment of benign prostatic hyperplasia-resection, vaporization or enucleation. Urologe A. 58(3):263-2
  15. Zeuschner P, Linxweiler J, Junker K (2019). Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn. 18:1-1
  16. Baumgart S, Meschkat P, Edelmann P, Heinzelmann J, Pryalukhin A, Bohle R, Heinzelbecker J, Stöckle M, Junker K (2019). MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle‑invasive bladder cancer. J Cancer Res Clin Oncol. 145(11): 2725–273
  17. Friedersdorff F, Putz J, Dreikorn K, Giessing M, Fornara P, Stöckle M, Schlomm T (2019). The 2018 annual report on the 26th annual meeting of the working group for kidney transplantation of the German Society of Urology in Berlin. Urologe A. 58(3):324-32
  18. Saar M, Abdeen MSKM, Niklas C, Al-Kailani ZTF, Siemer S, Stöckle M (2019). Trivialization of prostate cancer?: Stage shift and possible causes. Urologe A. 58(12):1461-146
  19. Zwick A, Bernhard M, Knoerck A, Linxweiler M, Schick B, Heinzelmann J, Smola S, Lohse S (2019). Monitoring kinetics reveals critical parameters of IgA-dependent granulocyte-mediated anti-tumor cell cytotoxicity. J Immunol Methods. 473:112644
  20. Gong X, Zhao H, Saar M, Peehl DM, Brooks JD (2019). miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. 7;3(2):119-132
2018
  1. Crossey F, Marx S, Hölters S, Schmitt K, Bohle RM, Schmidt T, Stöckle M, Sester U, Sester M, Janssen MWW.
    Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure.
    Urol Oncol. 2018  S1078-1439(18)30201-1
  2. Stöckle M, Junker K, Fornara P (2018). Low-risk Prostate Cancer Prior to or After Kidney Transplantation. Eur Urol Focus 4(2):148-15
  3. Linxweiler J, Shayesteh-Kheslat R, Fries P, Schneider G, Janssen M, Ohlmann CH, Stöckle M, Siemer S, Saar M (2018). Organ-Preserving Surgical Treatment of a Horseshoe Kidney Occupied by a Large Renal Cell Carcinoma with Extensive Venous Invasion: A Case Report. Urol Int.  100(2):245-24
  4. Ernst S, Saar M, Brenneis H, Kubale R, Ueberdiek S, Ohlmann CH, Stoeckle M, Heinzelbecker J (2018). Segmental Testicular Infarction: Case Series and Literature Review of a Rare Diagnosis in Men with Acute Testicular Pain. Urol Int. 101(1):114-11
  5. Heinzelbecker J, Stöckle M (2018). Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. Eur Urol. 73(2):303-304
  6. Janssen MWW, Linxweiler J, Philipps I, Bütow Z, Siemer S, Stöckle M, Ohlmann CH (2018). Kidney autotransplantation after nephrectomy and work bench surgery as an ultimate approach to nephron-sparing surgery. World J Surg Oncol. 16(1):3
  7. Linxweiler J, Saar M, Al-Kailani Z, Janssen M, Ezziddin S, Stöckle M, Siemer S, Ohlmann CH (2018). Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: perioperative and early oncological outcomes. Surg Oncol 27(2):138-14
  8. Loertzer P, Siemer S, Stöckle M, Ohlmann CH (2018). Robot-sewn ileoileal anastomosis during robot-assisted cystectomy. W J Urol 36(7):1079-108
  9. Ohlmann CH, Gross-Langenhoff M (2018). Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer. Urol Int. 100(1):66-7
  10. Linxweiler J, Körbel C, Müller A, Hammer M, Veith C, Bohle RM, Stöckle M, Junker K, Menger MD, Saar M (2018). A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases. Prostate. 78(9):664-67
  11. Janssen MWW, Linxweiler J, Terwey S, Rugge S, Ohlmann CH, Becker F, Thomas C, Neisius A, Thüroff JW, Siemer S, Stöckle M, Roos FC (2018). Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. PLoS One 13(5):e019642
  12. Breda A, Territo A, Gausa L, Tugcu V, Alcaraz A, Musquera M, Decaestecker K, Desender L, Stockle M, Janssen M, Fornara P, Mohammed N, Siena G, Serni S, Guirado S, Facundo C, Doumerc N (2018). Robot-assisted Kidney Transplantation: The European Experience. Eur Urol. 73(2):273-28
  13. Awwad HM, Ohlmann CH, Stoeckle M, Geisel J, Obeid R (2018). Serum concentrations of folate vitamers in patients with a newly diagnosed prostate cancer or hyperplasia. Clin Biochem 56:41-4
  14. Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Vermeulen SH, Oosterwijk E, Junker K, Roessler M, Alexiusdottir K, Sverrisdottir A, Radu MT, Ambert V, Eisen T, Warren AY, Rodríguez-Antona C, García-Donás J, Koudijs KKM, Böhringer S, Kiemeney LA, Rini B, Guchelaar HJ (2018). A genetic polymorphism in CTLA-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma. Clin Cancer Res. 24(10):2350-235
  15. Van Kessel KE, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NY, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC (2018). Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups. Clin Cancer Res 24(7):1586-159
  16. Territo A, Gausa L, Alcaraz A, Musquera M, Doumerc N, Decaestecker K, Desender L, Stockle M, Janssen M, Fornara P, Mohammed N, Siena G, Serni S, Sahin S, Tuǧcu V, Basile G, Breda A (2018). The European experience on robot-assisted kidney transplantation: minimum of one-year follow-up. BJU 122(2):255-26
  17. Siena G, Campi R, Decaestecker K, Tuğcu V, Sahin S, Alcaraz A, Musquera M, Territo A, Gausa L, Randon C, Stockle M, Janssen M, Fornara P, Mohammed N, Guirado L, Facundo C, Doumerc N, Vignolini G, Breda A, Serni S (2018). Robot-assisted Kidney Transplantation with Regional Hypothermia Using Grafts with Multiple Vessels After Extracorporeal Vascular Reconstruction: Results from the European Association of Urology Robotic Urology Section Working Group. Eur Urol Focus. 4(2):175-18
  18. Wemmert S, Linxweiler M, Lerner C, Bochen F, Kulas P, Linxweiler J, Smola S, Urbschat S, Wagenpfeil S, Schick B (2018). Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations. J Cancer Res Clin Oncol. 144(6):1129-1141